Please assess the completion status of the following clinical trial:

Trial Title: Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed recurrent or progressive supratentorial glioblastoma or anaplastic astrocytoma~* Measurable disease by MRI or CT scan~* No gliomatosis cerebri, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma~* Concurrent registration for the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) program~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 4,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 2.0 mg/dL~Renal:~* Creatinine less than 1.6 mg/dL~Other:~* No other concurrent malignancy except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 methods of effective contraception 1 month prior to, during, and for 1 month after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 2 prior chemotherapy regimens in adjuvant or metastatic setting~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Concurrent anticonvulsants allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).